Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Increasing value in research: cost evaluations in health professions education.

Schreurs S, Cleutjens K, Oude Egbrink MGA.

Med Educ. 2019 Dec;53(12):1171-1173. doi: 10.1111/medu.14007. No abstract available.

2.

Opening the black box of selection.

Schreurs S, Cleutjens K, Collares CF, Cleland J, Oude Egbrink MGA.

Adv Health Sci Educ Theory Pract. 2019 Oct 9. doi: 10.1007/s10459-019-09925-1. [Epub ahead of print]

PMID:
31598883
3.

Does selection pay off? A cost-benefit comparison of medical school selection and lottery systems.

Schreurs S, Cleland J, Muijtjens AMM, Oude Egbrink MGA, Cleutjens K.

Med Educ. 2018 Dec;52(12):1240-1248. doi: 10.1111/medu.13698. Epub 2018 Oct 15.

4.

Selection into medicine: the predictive validity of an outcome-based procedure.

Schreurs S, Cleutjens KB, Muijtjens AMM, Cleland J, Oude Egbrink MGA.

BMC Med Educ. 2018 Sep 17;18(1):214. doi: 10.1186/s12909-018-1316-x.

5.

Cathepsin K Deficiency Prevents the Aggravated Vascular Remodeling Response to Flow Cessation in ApoE-/- Mice.

Donners MM, Bai L, Lutgens SP, Wijnands E, Johnson J, Schurgers LJ, Liu CL, Daemen MJ, Cleutjens KB, Shi GP, Biessen EA, Heeneman S.

PLoS One. 2016 Sep 16;11(9):e0162595. doi: 10.1371/journal.pone.0162595. eCollection 2016.

6.

High-sensitive troponin T assay for the diagnosis of acute myocardial infarction: an economic evaluation.

Vaidya A, Severens JL, Bongaerts BW, Cleutjens KB, Nelemans PJ, Hofstra L, van Dieijen-Visser M, Biessen EA.

BMC Cardiovasc Disord. 2014 Jun 13;14:77. doi: 10.1186/1471-2261-14-77.

7.

Chemokines CCL3/MIP1α, CCL5/RANTES and CCL18/PARC are independent risk predictors of short-term mortality in patients with acute coronary syndromes.

de Jager SC, Bongaerts BW, Weber M, Kraaijeveld AO, Rousch M, Dimmeler S, van Dieijen-Visser MP, Cleutjens KB, Nelemans PJ, van Berkel TJ, Biessen EA.

PLoS One. 2012;7(9):e45804. doi: 10.1371/journal.pone.0045804. Epub 2012 Sep 21.

8.

Cathepsin K gene disruption does not affect murine aneurysm formation.

Bai L, Beckers L, Wijnands E, Lutgens SP, Herías MV, Saftig P, Daemen MJ, Cleutjens K, Lutgens E, Biessen EA, Heeneman S.

Atherosclerosis. 2010 Mar;209(1):96-103. doi: 10.1016/j.atherosclerosis.2009.09.001. Epub 2009 Sep 6.

PMID:
19775691
9.

Noninvasive diagnosis of ruptured peripheral atherosclerotic lesions and myocardial infarction by antibody profiling.

Cleutjens KB, Faber BC, Rousch M, van Doorn R, Hackeng TM, Vink C, Geusens P, ten Cate H, Waltenberger J, Tchaikovski V, Lobbes M, Somers V, Sijbers A, Black D, Kitslaar PJ, Daemen MJ.

J Clin Invest. 2008 Aug;118(8):2979-85. doi: 10.1172/JCI32767.

10.

Comparison of lipid-rich necrotic core size in symptomatic and asymptomatic carotid atherosclerotic plaque: Initial results.

Cappendijk VC, Kessels AG, Heeneman S, Cleutjens KB, Schurink GW, Welten RJ, Mess WH, van Suylen RJ, Leiner T, Daemen MJ, van Engelshoven JM, Kooi ME.

J Magn Reson Imaging. 2008 Jun;27(6):1356-61. doi: 10.1002/jmri.21359.

PMID:
18504755
11.

Comparison of single-sequence T1w TFE MRI with multisequence MRI for the quantification of lipid-rich necrotic core in atherosclerotic plaque.

Cappendijk VC, Heeneman S, Kessels AG, Cleutjens KB, Schurink GW, Welten RJ, Mess WH, van Suylen RJ, Leiner T, Daemen MJ, van Engelshoven JM, Kooi ME.

J Magn Reson Imaging. 2008 Jun;27(6):1347-55. doi: 10.1002/jmri.21360.

PMID:
18504754
12.

Cathepsin cysteine proteases in cardiovascular disease.

Lutgens SP, Cleutjens KB, Daemen MJ, Heeneman S.

FASEB J. 2007 Oct;21(12):3029-41. Epub 2007 May 23. Review.

PMID:
17522380
13.

Dead or alive: gene expression profiles of advanced atherosclerotic plaques from autopsy and surgery.

Sluimer JC, Kisters N, Cleutjens KB, Volger OL, Horrevoets AJ, van den Akker LH, Bijnens AP, Daemen MJ.

Physiol Genomics. 2007 Aug 20;30(3):335-41. Epub 2007 May 22.

PMID:
17519360
14.

Gene profiling of cathepsin K deficiency in atherogenesis: profibrotic but lipogenic.

Lutgens SP, Kisters N, Lutgens E, van Haaften RI, Evelo CT, de Winther MP, Saftig P, Daemen MJ, Heeneman S, Cleutjens KB.

J Pathol. 2006 Nov;210(3):334-43.

PMID:
16972305
15.

Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone.

Everts V, Korper W, Hoeben KA, Jansen ID, Bromme D, Cleutjens KB, Heeneman S, Peters C, Reinheckel T, Saftig P, Beertsen W.

J Bone Miner Res. 2006 Sep;21(9):1399-408.

16.

Disruption of the cathepsin K gene reduces atherosclerosis progression and induces plaque fibrosis but accelerates macrophage foam cell formation.

Lutgens E, Lutgens SP, Faber BC, Heeneman S, Gijbels MM, de Winther MP, Frederik P, van der Made I, Daugherty A, Sijbers AM, Fisher A, Long CJ, Saftig P, Black D, Daemen MJ, Cleutjens KB.

Circulation. 2006 Jan 3;113(1):98-107. Epub 2005 Dec 19.

PMID:
16365196
17.

Is there more than C-reactive protein and fibrinogen? The prognostic value of soluble CD40 ligand, interleukin-6 and oxidized low-density lipoprotein with respect to coronary and cerebral vascular disease.

Lobbes MB, Lutgens E, Heeneman S, Cleutjens KB, Kooi ME, van Engelshoven JM, Daemen MJ, Nelemans PJ.

Atherosclerosis. 2006 Jul;187(1):18-25. Epub 2005 Dec 19. Review.

PMID:
16360159
18.

Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis.

Ma X, Ziel-van der Made AC, Autar B, van der Korput HA, Vermeij M, van Duijn P, Cleutjens KB, de Krijger R, Krimpenfort P, Berns A, van der Kwast TH, Trapman J.

Cancer Res. 2005 Jul 1;65(13):5730-9.

19.

Gene profiling in atherosclerosis reveals a key role for small inducible cytokines: validation using a novel monocyte chemoattractant protein monoclonal antibody.

Lutgens E, Faber B, Schapira K, Evelo CT, van Haaften R, Heeneman S, Cleutjens KB, Bijnens AP, Beckers L, Porter JG, Mackay CR, Rennert P, Bailly V, Jarpe M, Dolinski B, Koteliansky V, de Fougerolles T, Daemen MJ.

Circulation. 2005 Jun 28;111(25):3443-52. Epub 2005 Jun 20.

PMID:
15967845
20.

Assessment of human atherosclerotic carotid plaque components with multisequence MR imaging: initial experience.

Cappendijk VC, Cleutjens KB, Kessels AG, Heeneman S, Schurink GW, Welten RJ, Mess WH, Daemen MJ, van Engelshoven JM, Kooi ME.

Radiology. 2005 Feb;234(2):487-92.

PMID:
15671004
21.

The loss of PTEN allows TCR alphabeta lineage thymocytes to bypass IL-7 and Pre-TCR-mediated signaling.

Hagenbeek TJ, Naspetti M, Malergue F, Garçon F, Nunès JA, Cleutjens KB, Trapman J, Krimpenfort P, Spits H.

J Exp Med. 2004 Oct 4;200(7):883-94. Epub 2004 Sep 27.

22.

In vivo detection of hemorrhage in human atherosclerotic plaques with magnetic resonance imaging.

Cappendijk VC, Cleutjens KB, Heeneman S, Schurink GW, Welten RJ, Kessels AG, van Suylen RJ, Daemen MJ, van Engelshoven JM, Kooi ME.

J Magn Reson Imaging. 2004 Jul;20(1):105-10.

PMID:
15221815
23.

Inflammation and restenosis: implications for therapy.

Donners MM, Daemen MJ, Cleutjens KB, Heeneman S.

Ann Med. 2003;35(7):523-31. Review.

PMID:
14649334
24.

Atherosclerotic plaque rupture: local or systemic process?

Lutgens E, van Suylen RJ, Faber BC, Gijbels MJ, Eurlings PM, Bijnens AP, Cleutjens KB, Heeneman S, Daemen MJ.

Arterioscler Thromb Vasc Biol. 2003 Dec;23(12):2123-30. Epub 2003 Sep 25. Review.

PMID:
14512372
25.

The dynamic extracellular matrix: intervention strategies during heart failure and atherosclerosis.

Heeneman S, Cleutjens JP, Faber BC, Creemers EE, van Suylen RJ, Lutgens E, Cleutjens KB, Daemen MJ.

J Pathol. 2003 Jul;200(4):516-25. Review.

PMID:
12845619
26.

Vasculin, a novel vascular protein differentially expressed in human atherogenesis.

Bijnens AP, Gils A, Jutten B, Faber BC, Heeneman S, Kitslaar PJ, Tordoir JH, de Vries CJ, Kroon AA, Daemen MJ, Cleutjens KB.

Blood. 2003 Oct 15;102(8):2803-10. Epub 2003 Jul 3.

PMID:
12842993
27.

Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging.

Kooi ME, Cappendijk VC, Cleutjens KB, Kessels AG, Kitslaar PJ, Borgers M, Frederik PM, Daemen MJ, van Engelshoven JM.

Circulation. 2003 May 20;107(19):2453-8. Epub 2003 Apr 28.

PMID:
12719280
28.

Genes potentially involved in plaque rupture.

Faber BC, Heeneman S, Daemen MJ, Cleutjens KB.

Curr Opin Lipidol. 2002 Oct;13(5):545-52. Review.

PMID:
12352019
29.

Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques.

Dhore CR, Cleutjens JP, Lutgens E, Cleutjens KB, Geusens PP, Kitslaar PJ, Tordoir JH, Spronk HM, Vermeer C, Daemen MJ.

Arterioscler Thromb Vasc Biol. 2001 Dec;21(12):1998-2003.

PMID:
11742876
30.

Identification of genes potentially involved in rupture of human atherosclerotic plaques.

Faber BC, Cleutjens KB, Niessen RL, Aarts PL, Boon W, Greenberg AS, Kitslaar PJ, Tordoir JH, Daemen MJ.

Circ Res. 2001 Sep 14;89(6):547-54.

PMID:
11557743
31.

Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype.

Lutgens E, Cleutjens KB, Heeneman S, Koteliansky VE, Burkly LC, Daemen MJ.

Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7464-9.

32.

An Sp1 binding site is essential for basal activity of the human prostate-specific transglutaminase gene (TGM4) promoter.

Dubbink HJ, Cleutjens KB, van der Korput HA, Trapman J, Romijn JC.

Gene. 1999 Nov 29;240(2):261-7.

PMID:
10580145
33.

A 6-kb promoter fragment mimics in transgenic mice the prostate-specific and androgen-regulated expression of the endogenous prostate-specific antigen gene in humans.

Cleutjens KB, van der Korput HA, Ehren-van Eekelen CC, Sikes RA, Fasciana C, Chung LW, Trapman J.

Mol Endocrinol. 1997 Aug;11(9):1256-65.

PMID:
9259317
34.

Androgen-regulated gene expression in prostate cancer.

Trapman J, Cleutjens KB.

Semin Cancer Biol. 1997 Feb;8(1):29-36. Review.

PMID:
9299579
35.

An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter.

Cleutjens KB, van der Korput HA, van Eekelen CC, van Rooij HC, Faber PW, Trapman J.

Mol Endocrinol. 1997 Feb;11(2):148-61.

PMID:
9013762
36.

Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer.

Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, Trapman J, Cleutjens K, Noordzij A, Visakorpi T, Kallioniemi OP.

Cancer Res. 1997 Jan 15;57(2):314-9.

37.

Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter.

Cleutjens KB, van Eekelen CC, van der Korput HA, Brinkmann AO, Trapman J.

J Biol Chem. 1996 Mar 15;271(11):6379-88.

Supplemental Content

Loading ...
Support Center